COR Therapeutics, Inc. Resets Guidance for Third Quarter and Year-End 2001.Business Editors/Health & Medical Writers SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif.--(BW HealthWire)--Oct. 3, 2001 COR Therapeutics, Inc. announced today that third quarter sales of INTEGRILIN(R) (eptifibatide) Injection to wholesalers in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. will be lower than previously anticipated. The Company said it expects U.S. sales to wholesalers to be approximately $53 million and worldwide sales to be approximately $59 million for the third quarter of 2001, primarily due to less than anticipated demand in September. The Company provided new earnings per share guidance for the third quarter of $0.01. For 2001, COR indicated that its new guidance for worldwide sales of INTEGRILIN is $240 to $250 million, and that earnings per share are expected to be $0.11 to $0.13, excluding a possible $10 million milestone payment related to European regulatory approval in angioplasty angioplasty (ăn`jēōplăs'tē), any surgical repair of a blood vessel, especially balloon angioplasty or percutaneous transluminal coronary angioplasty, a treatment of coronary artery disease. . The new earnings per share estimates for the quarter and year-end also reflect lower interest income on investments. COR said that U.S. hospital-based sales for July and August, according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. third-party data, were in line with expectations. The Company also noted that in a growing market, patient share for INTEGRILIN increased to over 51 percent in August, the highest ever reported by COR. On October 3, 2001, at 5:00 p.m. EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT , as part of the Company's efforts to ensure full disclosure to all parties, COR Therapeutics will webcast a conference call live via the Company's internet site to discuss these recent events. The call will be led by Vaughn M. Kailian, President and Chief Executive Officer. To access the live call or the 5-day archive, please log onto http://www.corr.com. Alternatively, the webcast may be accessed by logging onto http://www.vcall.com/NASApp/VCall/EventPage?ID=78561. Please connect to either website at least 10 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the live webcast. In addition to the historical information contained herein, this press release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve risks and uncertainties. Actual results may differ materially from the anticipated results discussed in such forward-looking statements, due to factors related to the commercialization of INTEGRILIN and other factors discussed in the Company's SEC reports, including, but not limited to, the Company's Report on Form 10-Q Form 10-Q See 10-Q. for the quarter ended June 30, 2001, and Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2000. Forward-looking statements are based on current expectations and the Company does not intend to update such information to reflect later events or developments. INTEGRILIN is a registered trademark of COR Therapeutics, Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion